Skip to content

Study · Animal study (in vivo) · 2002

8 results

[Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine].

Ostrovskaia RU, Liapina LA, Pastorova VE, Mirzoev TKh, Gudasheva TA, Seredenin SB, Ashmarin IP

Eksperimental'naia i klinicheskaia farmakologiia1 Mar 2002Cited by 1 (Europe PMC)

PMID12109290 (opens in a new tab)PepBankPUB-12109290
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In vivo, GVS-111 produced an antithrombotic effect.

    In plain wordsIn animals, GVS-111 reduced thrombosis.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseThrombosis
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1 mg/kg intraperitoneally or 10 mg/kg orally, once daily · intraperitoneal or oral · 10 daysAs given in this study.

    Source sentences

    Summary
    The experiments in vivo showed that the new nootropic prolyl-containing GVS-111 produces an antithrombotic effect, influencing various stages of the blood coagulation process.
    1 context sentence
    Summary · context
    These effects are manifested upon both intraperitoneal (1 mg/kg) and peroral (10 mg/kg) administration of GVS-111 (in both cases, a single daily treatment over a period of 10 days).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In vivo, GVS-111 exhibited anticoagulant properties.

    In plain wordsIn animals, GVS-111 reduced blood coagulation.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseCoagulation
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1 mg/kg intraperitoneally or 10 mg/kg orally, once daily · intraperitoneal or oral · 10 daysAs given in this study.

    Source sentences

    Summary
    GVS-111 exhibits anticoagulant and fibrinolytic properties and enhances fibrin destabilization by reducing the XIIIa factor activity.
    1 context sentence
    Summary · context
    These effects are manifested upon both intraperitoneal (1 mg/kg) and peroral (10 mg/kg) administration of GVS-111 (in both cases, a single daily treatment over a period of 10 days).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In vivo, GVS-111 exhibited fibrinolytic properties.

    In plain wordsIn animals, GVS-111 increased fibrin breakdown.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseFibrinolysis
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1 mg/kg intraperitoneally or 10 mg/kg orally, once daily · intraperitoneal or oral · 10 daysAs given in this study.

    Source sentences

    Summary
    GVS-111 exhibits anticoagulant and fibrinolytic properties and enhances fibrin destabilization by reducing the XIIIa factor activity.
    1 context sentence
    Summary · context
    These effects are manifested upon both intraperitoneal (1 mg/kg) and peroral (10 mg/kg) administration of GVS-111 (in both cases, a single daily treatment over a period of 10 days).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In vivo, GVS-111 enhanced fibrin destabilization.

    In plain wordsIn animals, GVS-111 increased fibrin destabilization.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseFibrin destabilization
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1 mg/kg intraperitoneally or 10 mg/kg orally, once daily · intraperitoneal or oral · 10 daysAs given in this study.

    Source sentences

    Summary
    GVS-111 exhibits anticoagulant and fibrinolytic properties and enhances fibrin destabilization by reducing the XIIIa factor activity.
    1 context sentence
    Summary · context
    These effects are manifested upon both intraperitoneal (1 mg/kg) and peroral (10 mg/kg) administration of GVS-111 (in both cases, a single daily treatment over a period of 10 days).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In vivo, GVS-111 reduced factor XIIIa activity.

    In plain wordsIn animals, GVS-111 reduced factor XIIIa activity.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseFactor XIIIa activity
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1 mg/kg intraperitoneally or 10 mg/kg orally, once daily · intraperitoneal or oral · 10 daysAs given in this study.

    Source sentences

    Summary
    GVS-111 exhibits anticoagulant and fibrinolytic properties and enhances fibrin destabilization by reducing the XIIIa factor activity.
    1 context sentence
    Summary · context
    These effects are manifested upon both intraperitoneal (1 mg/kg) and peroral (10 mg/kg) administration of GVS-111 (in both cases, a single daily treatment over a period of 10 days).
  6. 06LabIn vitro (cell-free)Mechanism

    In vitro, GVS-111 exhibited anticoagulant activity.

    In plain wordsIn lab tests, GVS-111 reduced coagulation.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseCoagulation in vitro
    Study

    n: not reported in source

    in vitro coagulation experiments
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10(-3)-10(-6) MAs given in this study.

    Source sentences

    Summary
    The same effects (anticoagulant, fibrinolytic, antifibrin-stabilizing) were observed in in vitro experiments with both GVS-111 (10(-3)-10(-6) M) and its main metabolite cyclo-L-prolylglycine (up to 10(-10) M).
  7. 07LabIn vitro (cell-free)Mechanism

    In vitro, GVS-111 exhibited fibrinolytic activity.

    In plain wordsIn lab tests, GVS-111 increased fibrin breakdown.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseFibrinolysis in vitro
    Study

    n: not reported in source

    in vitro coagulation experiments
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10(-3)-10(-6) MAs given in this study.

    Source sentences

    Summary
    The same effects (anticoagulant, fibrinolytic, antifibrin-stabilizing) were observed in in vitro experiments with both GVS-111 (10(-3)-10(-6) M) and its main metabolite cyclo-L-prolylglycine (up to 10(-10) M).
  8. 08LabIn vitro (cell-free)Mechanism

    In vitro, GVS-111 exhibited antifibrin-stabilizing activity.

    In plain wordsIn lab tests, GVS-111 reduced fibrin stabilization.

    Peptide
    Noopept (omberacetam)
    Outcome
    DecreaseFibrin stabilization in vitro
    Study

    n: not reported in source

    in vitro coagulation experiments
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10(-3)-10(-6) MAs given in this study.

    Source sentences

    Summary
    The same effects (anticoagulant, fibrinolytic, antifibrin-stabilizing) were observed in in vitro experiments with both GVS-111 (10(-3)-10(-6) M) and its main metabolite cyclo-L-prolylglycine (up to 10(-10) M).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.